Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  The Lancet Oncology

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(13)70174-8PMID 23684411
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Randomized trial of marker-directed versus standard schedule zoledronic acid for bone metastases from breast cancer.

  2012cited by this paper
• Five years of anti-resorptive activity after a single dose of zoledronate--results from a randomized double-blind placebo-controlled trial.

  2012cited by this paper
• Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid

  2012cited by this paper
• Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.

  2012cited by this paper
• Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D mutated metastatic colorectal cancer (mCRC)? A meta-analysis of 54 cases.

  2012cited by this paper
• Final analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients: ZARAS study.

  2011cited by this paper
• P323 Second interim analysis of dose density with zoledronic acid treatment in metastatic breast cancer patients. ZARAS study

  2011cited by this paper
• American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

  2011cited by this paper
• The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)

  2011cited by this paper
• Bisphosphonates as treatment of bone metastases.

  2010cited by this paper
• Effect of bisphosphonates on pain and quality of life in patients with bone metastases

  2009cited by this paper
• Zoledronic acid (ZOL) treatment (Rx) of ≥2 years in patients (pts) with metastatic bone disease (MBD) or multiple myeloma (MM): Six-month results from the LOTUZ study.

  2009cited by this paper
• Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases

  2008cited by this paper
• Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel.

  2008cited by this paper
• The bone microenvironment in metastasis; what is special about bone?

  2008cited by this paper
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid

  2008cited by this paper
• Pathologic fractures correlate with reduced survival in patients with malignant bone disease

  2007cited by this paper
• Moving into the future: treatment of bone metastases and beyond.

  2005cited by this paper
• Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

  2004cited by this paper
• Health-Related Quality of Life Among Patients With Breast Cancer Receiving Zoledronic Acid or Pamidronate Disodium for Metastatic Bone Lesions

  2004cited by this paper
• Bisphosphonates: clinical experience.

  2004cited by this paper
• Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma

  2003cited by this paper
• American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.

  2003cited by this paper
• Pain measurement tools and methods in clinical research in palliative care: recommendations of an Expert Working Group of the European Association of Palliative Care.

  2002cited by this paper
• Efficacy of Bisphosphonates in the Management of Skeletal Complications of Bone Metastases and Selection of Clinical Endpoints

  2002cited by this paper
• Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.

  2001cited by this paper
• Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases

  2000cited by this paper
• Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women.

  1998cited by this paper
• Skeletal complications of malignancy

  1997cited by this paper
• Vertebral fracture assessment using a semiquantitative technique

  1993cited by this paper
• Cox's regression model for counting processes: a large sample study : (preprint)

  1982cited by this paper

• Early detection of medication-related osteonecrosis of the jaw (MRONJ) in patients with metastatic breast cancer using FDG-PET/CT scans

  2026cites this paper
• Heterogeneous tissue-specific macrophages orchestrate metastatic organotropism of breast cancer: implications for promising therapeutics

  2025cites this paper
• Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis

  2025cites this paper
• Bone Metastases and Skeletal Complications: Information and Involvement of Patients with Cancer in the Treatment Pathway

  2025cites this paper
• Treatment of myeloma bone disease: When, how often, and for how long?

  2025cites this paper
• Atypical Femoral Fracture in Patients With Metastatic Bone Tumors: An Analysis Based on the Japanese Adverse Drug Event Reaction Database (JADER)

  2025cites this paper
• Dose optimisation to improve access to effective cancer medicines.

  2025cites this paper
• Place des marqueurs biochimiques du remodelage osseux dans le diagnostic et le suivi des métastases osseuses

  2025cites this paper
• Assessment of the benefits of bone modifying agents in the management of advanced breast, prostate, and lung cancers

  2025cites this paper
• Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies

  2024cites this paper
• Bridging the gap — Establishing a dental-oncology service in a cancer centre

  2024cites this paper
• Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study

  2024cites this paper
• A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer

  2024cites this paper
• Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy

  2024cites this paper
• Bone-modifying agents for bone metastasis in patients with breast cancer

  2024cites this paper
• Racial and Ethnic Disparities in European Breast Cancer Clinical Trials

  2024influential citation
• Brust- und gynäkologische Tumoren – medikamentöse Therapie ossärer Metastasen

  2023cites this paper
• Quality of life issues in patients with bone metastases: A systematic review

  2023cites this paper
• Interval Comparison of Zoledronic Acid Treatment in Patients with Metastatic Bone Disease, Is 4-Weekly or 12-Weekly More Effective?: A Systematic Review and Meta-analysis

  2023cites this paper
• Efficacy and safety of bone management agents administered at 12 weeks vs. 4 weeks in patients with bone metastases: A systematic review

  2023cites this paper
• Bone-modifying agents for non-small-cell lung cancer patients with bone metastases during the era of immune checkpoint inhibitors: A narrative review.

  2023cites this paper
• Bone-Targeted Therapy Regimen and Skeletal-Related Events in Patients Surviving Longer Than 2 Years With Metastatic Breast Cancer and Bone Metastasis.

  2023cites this paper
• Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312).

  2023cites this paper
• Patient-centred, self-funding dose optimisation trials as a route to reduce toxicity, lower cost and improve access to cancer therapy.

  2023cites this paper
• Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta-analysis.

  2023cites this paper
• Prevention of Skeletal-Related Events With Extended-Interval Denosumab: A Review of the Literature

  2023cites this paper
• Multicenter study on atypical femoral fractures in patients with bone metastases taking bone- modifying agents

  2023cites this paper
• AAOS Clinical Practice Guideline Summary: Treatment of Metastatic Carcinoma and Myeloma of the Femur

  2023cites this paper
• The Use of Intravenous Zoledronate May Reduce Retear Rate after Rotator Cuff Repair in Older Female Patients with Osteoporosis: A First In-Human Prospective Study

  2022cites this paper
• Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12.

  2022cites this paper
• Management of Progressive Radioiodine-Refractory Thyroid Carcinoma: Current Perspective

  2022cites this paper
• Cholesterol and Its Derivatives: Multifaceted Players in Breast Cancer Progression

  2022cites this paper
• Bigger isn't always better: the ESMO dose de-intensification guideline framework.

  2022cites this paper
• Pharmacological Prevention and Management of Skeletal-Related Events and Bone Loss in Individuals with Cancer.

  2022cites this paper
• Efficacy and Safety of Denosumab Versus Zoledronic acid in Suppressing Bone Metastases of Breast Cancer

  2022cites this paper
• Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers

  2022cites this paper
• "The use of bisphosphonates to treat skeletal complications in solid tumours".

  2021cites this paper
• Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons

  2021cites this paper
• GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages

  2021cites this paper
• Fracture Risk Evaluation of Bone Metastases: A Burning Issue

  2021cites this paper
• Bone-targeted Agents Used in Breast Cancer Patients with Bone Metastases

  2021cites this paper
• Cancer Patients at Risk for Medication-Related Osteonecrosis of the Jaw. A Case and Control Study Analyzing Predictors of MRONJ Onset

  2021cites this paper
• Chemotherapy for Pelvic Bone Tumors

  2021cites this paper
• Two-year results of a randomised trial comparing 4- versus 12-weekly bone-targeted agent use in patients with bone metastases from breast or castration-resistant prostate cancer

  2021cites this paper
• Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates

  2021cites this paper
• Updates in Management of Bone Metastatic Disease in Primary Solid Tumors with Systemic Therapies

  2021cites this paper
• Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management

  2021cites this paper
• Individualized Bone‐Protective Management in Long‐Term Cancer Survivors With Bone Metastases

  2021cites this paper
• Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations

  2021cites this paper
• Bone-modifying Agents (BMAs) in Breast Cancer.

  2021cites this paper
• Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey

  2021cites this paper
• Uptake of bone‐modifying agents in patients with HER2+ metastatic breast cancer with bone metastases – prospective data from a multi‐site Australian registry

  2021cites this paper
• Which Bone-Modifying Agent is Associated with Better Outcomes in Patients with Skeletal Metastases from Lung Cancer? A Systematic Review and Network Meta-analysis

  2021cites this paper
• Adjuvant bisphosphonate use in patients with early stage breast cancer: a physician survey

  2021cites this paper
• Review of Bone Modifying Agents in Metastatic Breast Cancer

  2021cites this paper
• Adjuvant bisphosphonate use in patients with early stage breast cancer: Patient perspectives on treatment acceptability and potential de-escalation

  2021cites this paper
• Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

  2020cites this paper
• Management of bone metastasis with intravenous bisphosphonates in breast cancer: a systematic review and meta-analysis of dosing frequency

  2020cites this paper
• A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy

  2020influential citation
• Association of Osteonecrosis of the Jaw With Zoledronic Acid Treatment for Bone Metastases in Patients With Cancer.

  2020cites this paper
• Real-world practice patterns and attitudes towards de-escalation of bone-modifying agents in patients with bone metastases from breast and prostate cancer: A physician survey

  2020cites this paper
• Pharmacologic Management of Metastatic Bone Disease.

  2020cites this paper
• Real-life use of denosumab 120 mg every 12 weeks in prolonged treatment over 2 years of patients with breast cancer bone metastases.

  2020cites this paper
• Impact of Extended-Interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Non–Small-Cell Lung Cancer and Small-Cell Lung Cancer Patients With Bone Metastases

  2020cites this paper
• Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China

  2020cites this paper
• A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer

  2020cites this paper
• Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review

  2020cites this paper
• Comment on ‘Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: A nationwide Italian survey’ by Alice Indini et al.

  2020cites this paper
• Advanced renal cell carcinoma (RCC) management: an expert panel recommendation from the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG)

  2020cites this paper
• Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• The limitations of today’s clinical guidance: Atypical femoral fracture and long-term bone-modifying agents in the oncology setting

  2020cites this paper
• Role of bone-modifying agents in advanced cancer.

  2020cites this paper
• State of art and advances on the treatment of bone metastases from breast cancer: a concise review.

  2020cites this paper
• Practical update for the use of bone-targeted agents in patients with bone metastases from metastatic breast cancer or castration-resistant prostate cancer.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cites this paper
• Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.

  2019cites this paper
• SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

  2019cites this paper
• Pharmacometrics and systems pharmacology for metabolic bone diseases.

  2019cites this paper
• Optimizing antiresorptive treatment in patients with bone metastases: time to initiation, switching strategies, and treatment duration

  2019cites this paper
• Zoledronate treatment duration is linked to bisphosphonate‐related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis

  2019cites this paper
• Sinomenine inhibits osteolysis in breast cancer by reducing IL‐8/CXCR1 and c‐Fos/NFATc1 signaling

  2019cites this paper
• Prevention and Treatment of Skeletal Complications

  2019cites this paper
• Role of Bisphosphonates in Breast Cancer Therapy

  2019cites this paper
• Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

  2019cites this paper
• Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case-control study.

  2019cites this paper
• De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis

  2019cites this paper
• Bisphosphonates: AHFS 92:24.

  2019cites this paper
• Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.

  2019cites this paper
• How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials.

  2019cites this paper
• Is De-escalated Bisphosphonates Therapy a Suitable Alternative to Standard Dosing in Malignant Tumor Patients With Bone Metastases: A Systematic Review and Meta-Analysis

  2019cites this paper
• Bone Metastasis of Breast Cancer.

  2019cites this paper
• Atypical femoral fractures from bisphosphonate in cancer patients – Review

  2019cites this paper
• Bone-Targeted Agents in Breast Cancer: Do We Now Have All the Answers?

  2019cites this paper
• Knochengesundheit bei Tumorpatienten

  2019cites this paper
• BOne HEalth ManagEment in Patients with Early Breast Cancer: A Retrospective Italian Osteoncology Center “Real-Life” Experience (BOHEME Study)

  2019cites this paper
• Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)

  2019cites this paper
• Use of Bone-Modifying Agents in Myeloma and Bone Metastases: How Recent Dosing Interval Studies Have Affected Our Practice.

  2018cites this paper
• De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?

  2018cites this paper
• Advances in treatment of metastatic breast cancer with bone metastasis.

  2018cites this paper